Barbara Ma

Assistant Professor: Melanoma/Cutaneous Oncology. Director of Cellular Therapy for Solid Tumors @weillcornell @WCMEnglanderIPM @nyphospital

[Pauline Funchain @FunchainMD]

Likely practice changing data in metastatic uveal melanoma: OptimUM-02 - ph2/3 in HLA 02:01 neg mUM vs investigator’s choice -Marlana Orloff @JeffersonUniv

ORR 39.5% v 1.9%
PFS 6.9 v 3.1 mo, HR 0.42
High rates of tox, but low rates of discontinuation

#ASCO26

[Hussein Tawbi, MD, PhD @HTawbi_MDPhD]

Impressive results for engineered T cell therapy w OBX-115 expertly presented by @DrBetofMDPhD tissue can be obtained by biopsy, outpatient low dose lymphodepletion, no IL-2 needed, 67% ORR, 93% DCR in PD-1 resistant melanoma pts, knocks it out of the park!

[WCMHemOncFellow @WCMHemOncFellow]

Some of our @WeillCornell HemOnc fellows at the #Tandem26 poster session last night! Lots of great #research projects – congrats to all!

[WCMHemOncFellow @WCMHemOncFellow]

Our @WeillCornell HemOnc fellows are involved with lots of #research this evening at #Tandem26. Congratulations to everyone for their involvement and hard work! Visit the posters and learn more if you’re attending the @ASTCT and @CIBMTR Meetings.

[Weill Cornell Medicine @WeillCornell]

Announcing the launch of the Weill Cancer Hub East, bringing together experts from @Princeton, @RockefellerUniv, Weill Cornell Medicine and @Ludwig_Cancer to innovate cancer treatment, supported by a generous donation from the Weill Family Foundation.

https://t.co/gUfyNYw7EO

[OncoDaily @oncodaily]

The newly elected steering committee members for 2025 of the @AACI_Cancer Physician Clinical Leadership Initiative and Cellular Therapy Initiative

https://t.co/05miy451Ni

@tinabhatnagar01 @rachnatshroff @BarbaraMaMD @Winterwond3r

#Cancer #Leadership #MedX #MedNews #Health #Medicine #OncoDaily #Oncology

[WCM Cutaneous Oncology @WCMCutaneousOnc]

ICYMI: A combination of #immunotherapy showed #cancer-free survival for 10 years in nearly half of patients with metastatic #Melanoma per @WeillCornell led research by Dr. Jedd Wolchok (@wolchokj) https://t.co/2m3uTuXyds

[Dr. Despina Siolas, MD, PhD @DrDespina123]

Grateful to @CRTFund for the generous grant & @GoHealio for spotlighting #PancreaticCancer awareness this #PancreaticCancerAwarenessMonth! Let’s keep pushing for progress this November and beyond! @DrMhidalgo @letswinpc @WCM_MeyerCancer @WCMGIcancer
https://t.co/oPItpwMCOa

[WCM Cutaneous Oncology @WCMCutaneousOnc]

#Research led by Dr. Jedd Wolchok (@wolchokj) on the combination of nivolumab and ipilimumab for metastatic #Melanoma may extend patient survival for six years or more compared to the previous average of 6.5 months: https://t.co/0sJG3yGbtk (cc: @YahooNews)

[Ronen Stoff, MD @RonenStoff]

Excellent session on developmental immunotherapy chaired by @DrBetofMDPhD which was topped off by her great presentation on the preliminary data of TILs for #melanoma brain mets, an unmet need. Encouraging signal but still more work to be done💪 #SMR24

[Allison Betof, MD, PhD, FASCO @DrBetofMDPhD]

IGNYTE study with RP1 in PD-1 refractory
melanoma (progressed while on tx) presented by Caroline Robert. 3y follow up. 33.6% ORR, 15% CR. mDOR 21.6 mo. 27% ORR in patients with had ipi+nivo. Nice responses in visceral no -injected lesions. mOS not reached. 4pt with G4 tox. #ESMO24 @OncoAlert

[NEJM @NEJM]

Presented at #ESMO24:

Among patients with advanced melanoma, median overall survival was 72 months with nivolumab plus ipilimumab and was 37 months with nivolumab alone, as compared with 20 months with ipilimumab alone.

Full CheckMate 067 trial results: https://t.co/dcXkj4NQw7

[Dr. Despina Siolas, MD, PhD @DrDespina123]

So proud of @christinemphmd for this poster presentation on our efforts to support female faculty development @WCM_MeyerCancer @WeillCornell @DrMhidalgo

[Pauline Funchain @FunchainMD]

Cancer emotions are complex, human behavior in the face of existential stress is complex, so many layers to why patients may withhold information or even intentionally lie, especially to docs in particular. (Patients: it’s ok, we get it)

-Krista Rubin #WIM2024 @AIMatMelanoma

[Pauline Funchain @FunchainMD]

Calling all cancer center admin 📢Specific points where we can expand bandwidth and personnnel to address the lack of diversity in clinical trials -Kellie Jack @WeillCornell #WIM2024 @AIMatMelanoma 🙏🌎

[Allison Betof, MD, PhD, FASCO @DrBetofMDPhD]

BRILLIANT well-being session at #WIM2024 by @PalamaraMcgrath. Absence of burnout DOES NOT equal well-being. “How do we take care of the people who take care of the people?” @AIMatMelanoma

[Pauline Funchain @FunchainMD]

What an honor to spend an afternoon with @EmensLeisha, @sitcancer president, discussing how women uniquely leverage networking and take on leadership, and how these styles differ in their reception from typical male patterns - the most thoughtful discussion of the day #wim2024

[Christine A. Garcia, MD, MPH @christinemphmd]

Celebrating the incredible women of @WeillCornell Hematology & Oncology! Our #HemeOnc Women Physicians’ Group spring meeting was an enlightening & enriching experience. #WomeninMedicine @HemOncWomenDocs @WCMHemOncFellow

[Allison Betof, MD, PhD, FASCO @DrBetofMDPhD]

For everyone interested in #TILcelltherapy and for centers working to implement this therapy, we have published consensus guidelines from the TIL working group. Checklists, patient selection criteria, IL-2 guidelines, etc. We hope you find it helpful! @AdamJSchoenfeld @OmidHamidMD @drkomanduri @HaanenJohn

https://t.co/d7ZFuy671A

[Ashish Saxena, MD, PhD @DrAshish_Saxena]

Kudos to Dr. Christine Garcia who stole the show at the American College of Surgeons (ACS) Cancer Conference in Austin, Tx!
Christine reviewed her QI initiatives at NYPH-WCMC during a panel on “Improving Quality in Cancer Programs: Best Practice Examples”